Top Pharmaceutical & Biotech Companies in the UK
Last updated: January 13, 2025
Total Companies
25
Total Investment
£4.5B+
Avg. Founded
2014
Unicorns
8
Overview
The UK has a thriving pharmaceutical and biotech industry, with a rich history of innovation and a strong global presence. This article examines the top 25 pharmaceutical and biotech companies in the UK, providing insights into their products, services, and recent developments.
Summary of the UK Pharmaceutical & Biotech Industry
The UK pharmaceutical and biotech industry is a significant contributor to the UK economy. In 2020, it generated £15 billion in gross value added, making it the third largest manufacturing sector in the UK. Two of the largest pharmaceutical companies globally, AstraZeneca and GlaxoSmithKline, are headquartered in the UK. However, the industry faces challenges such as rising production costs, increased competition from emerging markets, stricter regulatory controls, and the expiration of key patents. Despite these challenges, the industry has shown resilience, with many companies rationalizing their business strategies to reduce reliance on high-revenue patent drugs. This has supported revenue growth, along with rising life expectancy and an aging population, which have boosted domestic demand for medicines. The UK biotech sector is also experiencing robust growth, securing £808 million in investment during Q3 2024 despite global market pressures. This strong performance is part of a larger trend of growth, with the UK biotechnology market projected to reach US$227,707.0 million by 2030, with a compound annual growth rate of 16.6% from 2024 to 20304. The UK leads Europe in the number of new biotech start-ups, demonstrating its strength in the sector. In fact, 387 of the 1,382 biotechs in Europe originated in the UK.
Companies
| Company | Status | Founded | Headquarters | Description | Recent News |
|---|---|---|---|---|---|
Abingdon Health PLC | Public limited Company | 2008 | York, England | Specializes in developing and manufacturing rapid diagnostic tests, particularly lateral flow technology, and provides contract research and development, and manufacturing services. | Acquisition of IVDeology Holdings Limited, launch of the Saliva Pregnancy self-test in Boots, and launch of Abingdon Simply Test e-commerce website |
Advanced Medical Solutions Group PLC | Public | 1991 | Winsford, UK | Advanced Medical Solutions Group Plc is involved in the development, manufacturing, distribution, and design of wound care products and surgical products, including tissue adhesives, sutures, haemostats, internal fixation devices, and internal sealants. | Received regulatory approval to complete the acquisition of Peters Surgical, effective from 1 July 2024 |
Aptamer Group PLC | Public | 2008 | York, United Kingdom | Aptamer Group PLC provides binders for research, diagnostics, and therapeutics. The company offers Optimer, a platform for the discovery and development of optimized DNA and RNA aptamers, and Optimer +, which combines features of Optimer and antibodies. It serves bioprocessing and diagnostic institutes, as well as pharmaceutical scientists. | Aptamer Group has secured new contracts worth up to £471,000, including agreements with top global pharmaceutical companies to develop Optimer binders for clinical trials and therapeutic development. |
Arcinova | Private limited Company | 2015 | Alnwick, UK | A multiservice contract development and manufacturing organization (CDMO) that serves pharmaceutical and biotechnology companies across the globe in developing their life-changing medicines. | Acquired by Quotient Sciences, expanding Quotient’s service portfolio and integrating drug substance, drug product and clinical testing capabilities. |
Arecor Therapeutics PLC | Public limited Company | 2007 | Little Chesterford, United Kingdom | Arecor Therapeutics plc is a biopharmaceutical company focused on developing products in diabetes and other indications using its proprietary Arestat technology platform. It collaborates with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. | Arecor Therapeutics announced the closure of its subsidiary, Tetris Pharma, and a mutual agreement with Xeris BioPharma to return Ogluo rights, as part of a strategic shift towards higher-value R&D opportunities in insulin and oral peptide delivery. |
Aspire Pharma | Private | 2009 | UK | A global life sciences business devoted to delivering true value to patients, healthcare professionals, and the NHS through the development and supply of innovative products and medicines. It operates in various therapy areas including anti-infectives, central nervous system, dermatology, gastroenterology, oncology, ophthalmology, respiratory, and urology. | Aspire Pharma acquired Cenoté Pharma to strengthen its specialty pharma offering, particularly in treating carnitine deficiencies. |
Avacta Group PLC | Public limited Company | 2003 | London, England, UK | A clinical-stage oncology drug company developing novel cancer therapies and biotherapeutics using its Affimer technology platform. | Appointed Shaun Chilton as non-executive chairman, completed the first cohort and started dosing for the second cohort of the phase one trial of AVA6000, and raised gross proceeds of around GBP31.1 million through share placements. |
BAP Pharma Group | Private | 2011 | Marlow, UK | BAP Pharma Group are global leaders in clinical trial supply, specialising in comparator sourcing and secondary packaging. | Grand Opening Ceremony of its new US headquarters in Somerset, NJ on April 24, 2024 |
Belluscura PLC | Public | 2017 (as Belluscura Limited, renamed to Belluscura plc in 2017)[5] | London | Belluscura PLC is a United Kingdom-based medical device developer company focused on developing lightweight and portable oxygen enrichment technology, particularly the X-PLOR portable oxygen concentrator for patients with chronic lung diseases[1][2] | Raised £4.7 million through a merger with TMT Acquisition PLC, issued a £2.72 million convertible debt round and an additional £600,000 equity placement, and announced a change in major holdings[3][4] |
BenevolentAI | Public | 2013 | London, UK | A drug discovery company applying artificial intelligence (AI) to produce new medicines for the treatment of various diseases, including atopic dermatitis, ulcerative colitis, amyotrophic lateral sclerosis, and others[1][3][5] | Major strategic overhaul to return to its founding TechBio mission, exploring options to delist from Euronext Amsterdam[4] |
BioAscent | Private limited Company | 2013 | Newhouse, Scotland, UK | A leading provider of integrated drug discovery services, including de novo assay development, target analysis, compound screening, medicinal and synthetic chemistry, computational chemistry, and compound management[1] | Reported promising growth in the wake of sustained demand for its services, with 20% growth in compound management, 27% for in silico discovery, and 14% in biosciences in 2023[2] |
Bionical Solutions | Private limited Company | 2001 | Willington, England | Bionical Solutions provides clinical, commercial and digital services to life sciences companies in the UK and US, committed to improving patient outcomes. They deliver better access to medicines, improve patient adherence with prescribed treatments, and provide healthcare professionals with unique tools to enhance patient communication. | Bionical Solutions decided to demerge two of its business divisions, Multi-Channel Engagement (Commercial) and Health Outcomes (Clinical), into separate legal and operating entities within the parent company, with the demerger to complete on 1 August 2024. Gareth Williams was appointed CEO of the rebranded Health Outcomes (Clinical) division, now known as Bionical Health. |
Charnwood Molecular | Private | 1998 | Loughborough, UK | A contract research organization specializing in integrated drug discovery services within the pharmaceutical and biotechnology sectors, offering services including medicinal chemistry, pre-clinical process research & development, and synthetic chemistry. | Recently acquired by Concept Life Sciences after filing notices of intention to appoint administrators due to financial uncertainty. |
Crescent Pharma | Private | 2003 | Basingstoke, UK | A fast-growing independent generic pharmaceutical company specializing in the production and marketing of affordable generic medicines and over-the-counter consumer healthcare products. | Going public via a reverse merger with GlycoMimetics, capitalized with $200 million from investors |
Exscientia | Public | 2012 | Oxford, UK | An AI-driven pharma tech company committed to discovering, designing, and developing drugs using advanced AI processes and precision chemistry tools. | Entered into a definitive agreement to be acquired by Recursion Pharmaceuticals, expected to close in early 2025. |
Fishawack | Private | 2001 | Knutsford, UK | Specialist provider of medical communications and medical marketing services to global pharmaceutical, biotechnology, and medical device clients. | Rebranded as Avalere Health, unifying under a new name and brand to enhance its global commercialization services. |
Genedrive PLC | Public | 2007 (as Epistem Holdings Inc., renamed in July 2016) | Manchester, United Kingdom | Genedrive Plc develops and markets point of need molecular diagnostics platforms for identifying infectious diseases and pathogens, and provides other indications using its proprietary Polymerase Chain Reaction (PCR) technology. The company specializes in rapid, low-cost platforms for diagnosing genetic variants, aiding clinicians in making effective treatment decisions. | Genedrive executives have increased their shareholdings, and the company has announced the granting of share options to its senior management team. Additionally, Genedrive has proposed a fundraise to raise a minimum of £6.0 million to underpin and grow operations. |
Global Perspectives | Private limited Company | 1999 | London, UK | A dissolved private limited company. For the active entity, Global Perspectives, an IQVIA business, helps make clinical studies possible through innovative patient engagement strategies and a global network of patient supporters, moderators, and translators. | |
Helios Medical Communications | Private | 2015 | Macclesfield, Cheshire, UK | Experts in healthcare communications, translating complex scientific information into engaging and impactful campaigns[1] | Helios Global Group, the parent company, was sold to Telemos Capital following significant growth[3] |
Immunocore | Public | 2008 | Oxfordshire, England | A commercial-stage biotechnology company that discovered, developed and commercialized the world’s first approved T cell receptor (TCR) therapy, focusing on transformative innovation to benefit patients with cancer, infectious diseases, and autoimmune diseases. | Announced 2025 strategic priorities including plans for reaching more patients with melanoma and other diseases, and advancing its clinical portfolio with several ongoing and planned trials. |
Kymab Group | Private (acquired by Sanofi) | 2010 | Babraham, Cambridgeshire, United Kingdom | A leading biopharmaceutical group focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary Kymouse antibody platform. | Acquired by Sanofi to bolster Sanofi’s presence in immunology and deliver antibody treatments for immune diseases and immuno-oncology therapeutics. |
LGC | Private | 1842 | Teddington, UK | A global leader in life science tools, providing measurement tools, proficiency testing schemes, supply chain assurance standards, and specialty genomics reagents. LGC supports industries such as human healthcare, agri-food, and the environment. | Acquired DiaMex to enhance its serology and molecular quality control portfolio in December 2024 |
MD Group | Private (Acquired) | 1997 | Birkenhead, United Kingdom | The MD Group is a brand representing six individual companies working together to provide latent defects insurance, Building Control, and other insurance schemes to support the construction industry across the UK and in Europe. | HSB (UK and Ireland) completed its acquisition of MD Group to expand its insurance offerings within the UK construction sector. |
Medica Group PLC | Public | 2004 | Hastings, UK | An international provider of telemedicine services, primarily offering teleradiology reporting services through a network of consultant radiologists, radiographers, and specialist doctors. | Appointment of Tom Hargreaves as Chief Financial Officer (CFO) in early 2025. Launch of MedPath®, a digital pathology service, and Teleradiology+, a solution to transform radiology workflows. |
Metrion Biosciences | Private | 2015 | Cambridge, UK | Metrion Biosciences is a contract research organisation (CRO) specialising in high-quality preclinical drug discovery services, particularly in ion channel biology, cardiac safety profiling, and neuroscience services. | Secured £2.7m in new equity financing in 2024 to expand laboratories and services, and appointed Lee Patterson as the new CEO in December 2024. |
MRN Limited | Private limited Company | 2008 | Poole, Dorset, UK | Information technology consultancy activities | |
MyHealthChecked PLC | Public | 2008 | Cardiff, Wales | A United Kingdom-based consumer home-testing healthcare company offering at-home rapid tests, DNA, RNA, and blood sample collection kits. | Celebrated test kit registration in January 2025 |
Niox Group PLC | Public limited Company | 2006 | Oxford, England | A medical device company focused on point of care asthma diagnosis and management[4] | Announced results for the year ended 31 December 2023, highlighting revenue growth and other financial highlights[4] |
Novacyt S.A. | Public | Velizy Villacoublay, France | Novacyt SA is an international molecular diagnostics company that develops, manufactures, and commercialises a range of molecular assays and instrumentation. It provides integrated technologies and services focused on genomic medicine, including human health, animal health, and environmental sectors. | Completion of acquisition of Yourgene Health plc, further expansion of cost reduction programme, and London Vet Show: Launch of animal multiplex assays | |
Oncimmune Holdings PLC | Public | Leeds, United Kingdom | Oncimmune Holdings PLC is a cancer detection company engaged in developing and commercializing its proprietary EarlyCDT platform technology, primarily focused on the growing fields of immuno-oncology, autoimmune disease, and infectious diseases. | Shares in Oncimmune Holdings PLC climbed 11% on Friday after it announced certain updates. | |
Optibiotix Health PLC | Public limited Company | 2006 | York, England | OptiBiotix Health Plc is a life sciences company operating in the modulation of the human microbiome, developing technologies and products for food ingredients, supplements, and active compounds to impact human physiology and health. | OptiBiotix Health PLC Launch of Dr Morepen LightLife in India, Directorate Change, Issue of Options[3] |
Oxford BioDynamics PLC | Public limited Company | 2007 | Oxford, UK | An international biotechnology company advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases. | Announced a leadership change with the resignation of CEO Dr. Jon Burrows and the appointment of Iain Ross as Executive Chairman, and is seeking additional funding through a potential equity raise. |
Oxford Metrics PLC | Public | 1984 | Yarnton, United Kingdom | Oxford Metrics plc operates as a smart sensing and software company in the United Kingdom and internationally. It engages in the development, production, and sale of computer software and equipment for the engineering, entertainment, and life science markets. | Oxford Metrics PLC agreed to buy Sempre Group Holdings Ltd for up to GBP5.5 million to add to its smart manufacturing division. |
Perspectum | Private | 2012 | Oxford, England | Perspectum is a global medical technology company delivering advanced digital technologies to help clinicians provide better care for patients with chronic metabolic diseases, multi-organ pathology, and cancer. It focuses on precision medicine using advanced imaging and genetics to enable early detection, diagnosis, and targeted treatment. | Completed a $36 million first close of its Series C funding round led by Oppenheimer Holdings in January 2023. |
Physiomics PLC | Public limited Company | 2001 | Abingdon, England | A leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions | Completed a placing to fund growth opportunities, launched a WRAP Retail Offer, and awarded a new contract with a globally recognised pharmaceutical client |
Poolbeg Pharma PLC | Public | 2021 | London, United Kingdom | Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company focused on acquiring, developing and commercialising innovative medicines for unmet medical needs, particularly in areas such as cancer immunotherapy-induced cytokine release syndrome, infectious diseases, and metabolic conditions. | Entered into non-binding discussions for an all-share acquisition by HOOKIPA Pharma Inc. and proposed collaboration with Gilead Sciences for investment up to $8.7495 million. |
Prime Global Medical Communications | Private limited Company | 1998 | Knutsford, England | A global medical communications and market access group providing full-service professional communications, including healthcare strategy and consultancy, scientific and medical communications, consumer health, patient-integrated science, and market access. | Acquired Aventine Consulting to bolster its U.S. evidence and access presence |
Proteome Sciences PLC | Public limited Company | 1993 | Cobham, Surrey, United Kingdom | Proteome Sciences is an established leader in CRO outsourced services to quantitate proteins and peptides in complex solid and fluid biological samples. We use high sensitivity proprietary technologies to detect biomarkers across major human diseases in areas of significant unmet need where biomarkers have the potential to transform disease management and treatment. | Proteome Sciences has secured a contract win from a US biopharmaceutical company using the Company’s mass spectrometry services for the analysis of samples for an on-going clinical trial. The company has also completed the installation and setup of equipment in its new US laboratory in San Diego, California, and is now fully operational. |
Proton Motor Power Systems PLC | Public limited Company | 2006 | London, England | The company is focused on stationary solutions, as well as mobile, maritime, and rail applications. It engages in the development and manufacturing of fuel cells, stacks, and hybrid systems to implement customized solutions. | Proton Motor Power Systems PLC intends to delist from AIM and wind down its operations by the end of 2024 due to failure to secure additional funding. |
Provexis PLC | Public limited Company | 2004 | Reading, England | Specialising in functional food and dietary supplements, particularly the patented natural extract from tomatoes known as Fruitflow® | Revenue more than doubled in the six months to September 30, 2024, and the company is looking forward to expansion, including a potential entry into the Chinese market and the launch of an Irish subsidiary |
Qualasept Holdings | Private limited with Share Capital | 2016 | Corsham, United Kingdom | Qualasept Holdings Limited operates in the activities of other holding companies sector. It is the parent company of several subsidiaries including Bath ASU, Pharmaxo, and Microgenetics. | Provided Series A financing to Event Store in 2020 for the development of EventStoreDB and Event Store Cloud |
Quay Pharmaceuticals | Private limited with Share Capital | 2002 | Deeside Industrial Park, UK | A contract development manufacturing organisation (CDMO) specializing in formulation research and development, clinical and commercial manufacturing of new chemical entities, biologicals, and live biotherapeutics. | Acquired by SGS to become the global Centre of Excellence for Formulation, Research and Development within SGS Health Science. |
Quotient Sciences | Private | 2004 | Nottinghamshire, England, UK | Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway, including pre-formulation screening, formulation development and optimization, first-in-human trials, and clinical and commercial manufacturing services. | Announced major changes to its commercial and scientific executive leadership team, including new appointments of Dr. Andrew Lewis as Chief Scientific Officer, Kieron Hall as Chief Marketing Officer, and Eric Bironneau as Chief Business Officer in March 2024. |
Renalytix PLC | Public limited Company | 2018 | London, United Kingdom | An artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs[5] | Potential takeover fell through; advanced discussions with key stakeholders; delisting risk from Nasdaq; transition to OTCQB Venture Market[2][3] |
Richmond Pharmacology | Private | 2001 | London, UK | A UK-based contract research organization conducting early phase clinical trials and clinical research, known for its speed and precision in bringing life-changing therapies to market. | Richmond Pharmacology has dosed the first person in the world with a new genetic therapy for ATTR Amyloidosis using CRISPR-Cas9 technology and has undergone a brand refresh, changing its name to simply 'Richmond'. |
Sareum Holdings PLC | Public limited Company | 2004 | Cambridge, UK | Sareum Holdings plc is a biotechnology company focused on developing next-generation kinase inhibitors for autoimmune diseases and cancer, particularly targeting TYK2 and JAK1 pathways. | Termination of the licensing agreement for its cancer drug candidate SRA737 by a U.S.-based biopharma company, effective in March 2025. The company is now focusing on its in-house projects, especially SDC-1801. |
Shield Therapeutics PLC | Public limited Company | 2015 | Gateshead, England | A patient-focused, commercial stage pharmaceutical company on a mission to improve the lives of people suffering from iron deficiency, enabling them to enjoy the things that make a difference in their everyday lives. The lead medicine is ACCRUFeR® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anemia. | KYE Pharmaceuticals Inc. filed a New Drug Submission for Accrufer® in Canada, and the Korean Food and Drug Administration agreed that a single pharmacokinetic study is the only additional study needed for Accrufer® |
SkinBioTherapeutics PLC | Public | Manchester, United Kingdom | A life science company focused on skin health, harnessing the microbiome for human health through its proprietary platform technology, SkinBiotix®. | Acquired Bio-Tech Solutions Limited for £1.25 million on October 11, 2024 | |
Surgical Innovations Group PLC | Public limited Company | 1988 | Leeds, West Yorkshire, UK | Manufacturer and distributor of medical technology, focusing on Minimally Invasive Surgery (MIS) and providing sustainable solutions to reduce the environmental footprint of surgery | Announced record revenue of GBP12.0 million, signed two exclusive multi-year UK distributing agreements, and reported a pretax loss of GBP728,000 in 2023 |
Sygnature Discovery | Private | 2004 | Nottingham, UK | A world-leading integrated drug discovery and non-clinical solutions provider, offering expertise across a broad range of therapeutic areas and biological target classes. | Acquired NuChem Sciences, a leading discovery CRO in North America, to expand its global footprint |
Synairgen PLC | Public limited Company | 2003 | Southampton, UK | Synairgen is a specialist respiratory biotech company developing an investigative inhaled interferon beta candidate (SNG001) for severe viral lung infections. | Proposed fundraising to raise a minimum of £18 million and a maximum of £19 million through the conditional subscription of new Ordinary Shares. |
Tissue Regenix Group PLC | Public limited Company | 2006 | Garforth, Leeds, England | A pioneering, international medical technology company focusing on the development of regenerative products utilising dCELL® and BioRinseTM technologies. | Extended distribution agreement with Arthrex, Inc. (November 2024) |
Trellus Health PLC | Public limited Company | 2020 | London, United Kingdom | Trellus Health plc is a United Kingdom-based health services company, which is engaged in providing solutions and services for chronic condition management, particularly focusing on chronic costly GI conditions such as inflammatory bowel disease (IBD)[2] | Trellus Health PLC shares surged on Tuesday after the company announced a collaboration with Johnson & Johnson Health Care Systems Inc to integrate its Trellus Elevate platform into a patient support programme in the US[3][5] |
Tristel PLC | Public limited Company | 2003 | Snailwell, Cambridgeshire, UK | Tristel is an infection prevention company that develops innovative solutions to prevent the transmission of microbes using chlorine dioxide as a high-performance disinfectant.[1] | Tristel reported FY24 revenue of GBP41.9M and EPS of GBX13.54[4] |
ValiRx PLC | Public | 2000 | Nuneaton, UK | A biopharmaceutical company that develops oncology therapeutics and companion diagnostics, including products like VAL201 for prostate cancer and VAL401 for lung cancer. | Acquisition of patents and intellectual property from FIT Biotech and a joint-venture agreement with Alpha Blue Ocean |
Venture Life Group PLC | Public limited Company | 2005 | Bracknell, Berkshire, UK | Develops and commercializes healthcare products in the self-care market globally | Acquired Health and Her Ltd. from Wales Angel Co-investment Fund and Development Bank of Wales Plc on October 30, 2024 |
Vianet Group PLC | Public limited Company | 2005 | Stockton On Tees, UK | Vianet Group provides data insight and reporting, with over 300 customers and more than 230,000 devices connected to their platform. | Announced the repurchase and cancellation of 10,000 ordinary shares; acquired the trade and assets of Beverage Metrics |
Waymade | Public limited Company | 1984 | Basildon, United Kingdom | A global specialty pharmaceutical business focusing on product development, licensing and commercialisation of generic and niche medicines. | Waymade Capital forms part of a consortium led by Duke Street to acquire Medi-Globe Corp, a German medical devices business. |
Xeros Technology Group PLC | Public limited Company | 2013 | Rotherham, United Kingdom | Xeros Technology Group PLC is a United Kingdom-based company engaged in providing technology solutions for the laundry and apparel industries, focusing on developing patented technologies to reduce the environmental impact of how industries make and care for clothes.[2] | Change in major shareholdings, including adjustments by First Equity Limited and Premier Miton Group[3][4] |
Zecare | Private | 2005 | St. Neots, Cambridgeshire, UK | ||
Ellipses Pharma | Private | 2018 | London, UK | A global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug development model that combines unbiased vetting of potential drug candidates with an uninterrupted flow of capital to minimize the time it takes to advance drugs through the clinical trial process and reach patients. | Ellipses Pharma launched a pioneering clinical trial programme in the Middle East, focusing on its next-generation selective RET inhibitor (EP0031/A400) for RET-altered tumours, and entered into an exclusive licensing agreement with SunRock Biopharma for a first-in-class bifunctional HER3:TRAIL fusion protein (EP0017)[2][3] |
CellCentric | Private limited Company | 2003 | Cambridge, UK | CellCentric is a clinical stage biotech company focused on the development of a p300/CBP inhibitor to treat specific cancer types, notably multiple myeloma. | Presented latest clinical data on inobrodib, a novel oral drug, at ASH24, showing promising efficacy and safety in treating multiple myeloma. |
Evox Therapeutics | Private | Oxford, UK | A biotechnology company focused on harnessing and engineering the natural delivery capabilities of extracellular vesicles (exosomes) to develop a new class of biotherapeutics for treating severe diseases, particularly targeting the brain and central nervous system. | Dr. Per Lundin appointed as Chief Executive Officer, acquisition of engEx-AAV™ technology platform from Codiak Biosciences | |
Ascend Gene & Cell Therapies | Private | 2023 | London, UK | Ascend is a specialist AAV development partner supporting the next-generation of life-science innovators in bringing gene therapy products to patients. They offer process development, clinical manufacturing, and analytical and regulatory support for biotech companies. | Expanded US footprint through merger with Advanced BioScience Laboratories, and raised over $130M in funding to enhance manufacturing capabilities. |
AviadoBio | Private limited Company | 2019 | London, England | AviadoBio is a pioneering startup in the healthcare sector, specifically in the field of gene therapy, focused on developing and delivering innovative gene therapies for individuals suffering from severe neurodegenerative diseases such as frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). | Astellas and AviadoBio announced an exclusive option and license agreement for AVB-101, an investigational, AAV-based gene therapy in Phase 1/2 development for frontotemporal dementia with mutations in the progranulin (GRN) gene. |
OMass | Private limited Company | 2016 | Oxford, England | A biotechnology company harnessing native mass spectrometry to drive drug discovery, focusing on rare and immunological diseases, and developing small molecule therapeutics using its proprietary OdyssION™ technology platform. | Selected by Fierce Biotech as a ‘Fierce 15’ winner for 2024, advancing its lead program for Congenital Adrenal Hyperplasia and expanding its pipeline in immunology |
Bit.bio | Private limited Company | 2016 | Cambridge, United Kingdom | Bit Bio is a synthetic biology company providing human cells for research, drug discovery and cell therapy. The company applies a patented safe harbour gene-targeting approach to inducibly express transcription factor combinations that reprogram human induced pluripotent stem cells (iPSCs) into highly defined and mature human cell types. | bit.bio's opti-ox™ technology has gained unprecedented global patent coverage, including approvals in the U.S., China, and South Korea, and pending in other key markets like Australia and Japan. |
Osler Diagnostics | Private | 2016 | Oxford, England | Osler Diagnostics is a healthcare technology startup aiming to transform global healthcare through its innovative product, the Osler Origin®, a portable diagnostic device capable of performing a wide range of tests in a rapid, low-cost, and easy-to-use manner. | M&G’s Catalyst strategy has invested in Osler Diagnostics to support the advancement of the Osler Origin product through regulatory activities and towards market launch. |
Touchlight | Private | 2007 | Hampton, UK | Touchlight is a biotechnology company focused on the production of synthetic DNA vectors, specifically its proprietary doggybone DNA (dbDNA™), which is used in genetic medicine, including viral vectors, mRNA, and DNA-based therapies. | Touchlight completed the expansion of one of the world’s largest DNA manufacturing facilities in London, UK, and received FDA clearance for an Investigational New Drug (IND) application using dbDNA. |
Crescendo Biologics | Private | 2007 | Cambridge, UK | Crescendo Biologics is a clinical-stage immuno-oncology company focused on developing novel T cell-enhancing therapeutics, particularly using its proprietary Humabody® VH platform. | Secured $32 million to expand the Phase 1b clinical trial of CB307 with a new pembrolizumab combination expansion cohort in PSMA+ solid tumours. |
Pulmocide | Private | 2007 | London, UK | Pulmocide is a biopharmaceutical company focusing on the discovery and development of inhaled medicine for the treatment of life-threatening fungal and viral infections of the respiratory tract. | Pulmocide announced a presentation at the 43rd Annual J.P. Morgan Healthcare Conference and is conducting Phase 3 clinical trials for opelconazole for the treatment of Invasive Pulmonary Aspergillosis[3] |
Quell Therapeutics | Private | 2019 | London, UK | Quell Therapeutics is a biotechnology company focused on developing engineered T regulatory (Treg) cell therapies for autoimmune diseases and preventing rejection in organ transplantation. | Collaboration with AstraZeneca to develop T-regulatory cell therapies for Type 1 diabetes and inflammatory bowel disease. |
F2G | Private limited Company | 1998 | Manchester, England | F2G is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening rare fungal infections. | F2G secured $100 million in funding led by AMR Action Fund to advance late-stage development and commercialization of its novel antifungal drug candidate, olorofim. |
TauRx Pharmaceuticals | Private | 2002 | Aberdeen, Scotland; Incorporated in Singapore | TauRx Pharmaceuticals Ltd is a life sciences/pharmaceutical company focused on developing treatments for neurodegenerative diseases, particularly Alzheimer's disease, through protein aggregation inhibitors. | Dundee Corporation sold 8,000 shares of TauRx Pharmaceuticals Ltd to a private investor for US$1 million in September 2024. |
Artios Pharma | Private limited Company | 2015 | Cambridge, England | Artios is a leading independent DNA Damage Response company committed to discovering and developing groundbreaking DDR therapeutics to help patients suffering from a broad range of devastating and difficult-to-treat cancers. | Artios Announces Initiation of Phase 2 Randomized Trial for ATR Inhibitor ART0380 plus Gemcitabine in Patients with Platinum Resistant Ovarian Cancer |
Abingdon Health PLC
About
Specializes in developing and manufacturing rapid diagnostic tests, particularly lateral flow technology, and provides contract research and development, and manufacturing services.
Recent News
Acquisition of IVDeology Holdings Limited, launch of the Saliva Pregnancy self-test in Boots, and launch of Abingdon Simply Test e-commerce website
Advanced Medical Solutions Group PLC
About
Advanced Medical Solutions Group Plc is involved in the development, manufacturing, distribution, and design of wound care products and surgical products, including tissue adhesives, sutures, haemostats, internal fixation devices, and internal sealants.
Recent News
Received regulatory approval to complete the acquisition of Peters Surgical, effective from 1 July 2024
Aptamer Group PLC
About
Aptamer Group PLC provides binders for research, diagnostics, and therapeutics. The company offers Optimer, a platform for the discovery and development of optimized DNA and RNA aptamers, and Optimer +, which combines features of Optimer and antibodies. It serves bioprocessing and diagnostic institutes, as well as pharmaceutical scientists.
Recent News
Aptamer Group has secured new contracts worth up to £471,000, including agreements with top global pharmaceutical companies to develop Optimer binders for clinical trials and therapeutic development.
Arcinova
About
A multiservice contract development and manufacturing organization (CDMO) that serves pharmaceutical and biotechnology companies across the globe in developing their life-changing medicines.
Recent News
Acquired by Quotient Sciences, expanding Quotient’s service portfolio and integrating drug substance, drug product and clinical testing capabilities.
Arecor Therapeutics PLC
About
Arecor Therapeutics plc is a biopharmaceutical company focused on developing products in diabetes and other indications using its proprietary Arestat technology platform. It collaborates with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products.
Recent News
Arecor Therapeutics announced the closure of its subsidiary, Tetris Pharma, and a mutual agreement with Xeris BioPharma to return Ogluo rights, as part of a strategic shift towards higher-value R&D opportunities in insulin and oral peptide delivery.
Aspire Pharma
About
A global life sciences business devoted to delivering true value to patients, healthcare professionals, and the NHS through the development and supply of innovative products and medicines. It operates in various therapy areas including anti-infectives, central nervous system, dermatology, gastroenterology, oncology, ophthalmology, respiratory, and urology.
Recent News
Aspire Pharma acquired Cenoté Pharma to strengthen its specialty pharma offering, particularly in treating carnitine deficiencies.
Avacta Group PLC
About
A clinical-stage oncology drug company developing novel cancer therapies and biotherapeutics using its Affimer technology platform.
Recent News
Appointed Shaun Chilton as non-executive chairman, completed the first cohort and started dosing for the second cohort of the phase one trial of AVA6000, and raised gross proceeds of around GBP31.1 million through share placements.
BAP Pharma Group
About
BAP Pharma Group are global leaders in clinical trial supply, specialising in comparator sourcing and secondary packaging.
Recent News
Grand Opening Ceremony of its new US headquarters in Somerset, NJ on April 24, 2024
Belluscura PLC
About
Belluscura PLC is a United Kingdom-based medical device developer company focused on developing lightweight and portable oxygen enrichment technology, particularly the X-PLOR portable oxygen concentrator for patients with chronic lung diseases[1][2]
Recent News
Raised £4.7 million through a merger with TMT Acquisition PLC, issued a £2.72 million convertible debt round and an additional £600,000 equity placement, and announced a change in major holdings[3][4]
BenevolentAI
About
A drug discovery company applying artificial intelligence (AI) to produce new medicines for the treatment of various diseases, including atopic dermatitis, ulcerative colitis, amyotrophic lateral sclerosis, and others[1][3][5]
Recent News
Major strategic overhaul to return to its founding TechBio mission, exploring options to delist from Euronext Amsterdam[4]
BioAscent
About
A leading provider of integrated drug discovery services, including de novo assay development, target analysis, compound screening, medicinal and synthetic chemistry, computational chemistry, and compound management[1]
Recent News
Reported promising growth in the wake of sustained demand for its services, with 20% growth in compound management, 27% for in silico discovery, and 14% in biosciences in 2023[2]
Bionical Solutions
About
Bionical Solutions provides clinical, commercial and digital services to life sciences companies in the UK and US, committed to improving patient outcomes. They deliver better access to medicines, improve patient adherence with prescribed treatments, and provide healthcare professionals with unique tools to enhance patient communication.
Recent News
Bionical Solutions decided to demerge two of its business divisions, Multi-Channel Engagement (Commercial) and Health Outcomes (Clinical), into separate legal and operating entities within the parent company, with the demerger to complete on 1 August 2024. Gareth Williams was appointed CEO of the rebranded Health Outcomes (Clinical) division, now known as Bionical Health.
Charnwood Molecular
About
A contract research organization specializing in integrated drug discovery services within the pharmaceutical and biotechnology sectors, offering services including medicinal chemistry, pre-clinical process research & development, and synthetic chemistry.
Recent News
Recently acquired by Concept Life Sciences after filing notices of intention to appoint administrators due to financial uncertainty.
Crescent Pharma
About
A fast-growing independent generic pharmaceutical company specializing in the production and marketing of affordable generic medicines and over-the-counter consumer healthcare products.
Recent News
Going public via a reverse merger with GlycoMimetics, capitalized with $200 million from investors
Exscientia
About
An AI-driven pharma tech company committed to discovering, designing, and developing drugs using advanced AI processes and precision chemistry tools.
Recent News
Entered into a definitive agreement to be acquired by Recursion Pharmaceuticals, expected to close in early 2025.
Fishawack
About
Specialist provider of medical communications and medical marketing services to global pharmaceutical, biotechnology, and medical device clients.
Recent News
Rebranded as Avalere Health, unifying under a new name and brand to enhance its global commercialization services.
Genedrive PLC
About
Genedrive Plc develops and markets point of need molecular diagnostics platforms for identifying infectious diseases and pathogens, and provides other indications using its proprietary Polymerase Chain Reaction (PCR) technology. The company specializes in rapid, low-cost platforms for diagnosing genetic variants, aiding clinicians in making effective treatment decisions.
Recent News
Genedrive executives have increased their shareholdings, and the company has announced the granting of share options to its senior management team. Additionally, Genedrive has proposed a fundraise to raise a minimum of £6.0 million to underpin and grow operations.
Global Perspectives
About
A dissolved private limited company. For the active entity, Global Perspectives, an IQVIA business, helps make clinical studies possible through innovative patient engagement strategies and a global network of patient supporters, moderators, and translators.
Recent News
Helios Medical Communications
About
Experts in healthcare communications, translating complex scientific information into engaging and impactful campaigns[1]
Recent News
Helios Global Group, the parent company, was sold to Telemos Capital following significant growth[3]
Immunocore
About
A commercial-stage biotechnology company that discovered, developed and commercialized the world’s first approved T cell receptor (TCR) therapy, focusing on transformative innovation to benefit patients with cancer, infectious diseases, and autoimmune diseases.
Recent News
Announced 2025 strategic priorities including plans for reaching more patients with melanoma and other diseases, and advancing its clinical portfolio with several ongoing and planned trials.
Kymab Group
About
A leading biopharmaceutical group focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary Kymouse antibody platform.
Recent News
Acquired by Sanofi to bolster Sanofi’s presence in immunology and deliver antibody treatments for immune diseases and immuno-oncology therapeutics.
LGC
About
A global leader in life science tools, providing measurement tools, proficiency testing schemes, supply chain assurance standards, and specialty genomics reagents. LGC supports industries such as human healthcare, agri-food, and the environment.
Recent News
Acquired DiaMex to enhance its serology and molecular quality control portfolio in December 2024
MD Group
About
The MD Group is a brand representing six individual companies working together to provide latent defects insurance, Building Control, and other insurance schemes to support the construction industry across the UK and in Europe.
Recent News
HSB (UK and Ireland) completed its acquisition of MD Group to expand its insurance offerings within the UK construction sector.
Medica Group PLC
About
An international provider of telemedicine services, primarily offering teleradiology reporting services through a network of consultant radiologists, radiographers, and specialist doctors.
Recent News
Appointment of Tom Hargreaves as Chief Financial Officer (CFO) in early 2025. Launch of MedPath®, a digital pathology service, and Teleradiology+, a solution to transform radiology workflows.
Metrion Biosciences
About
Metrion Biosciences is a contract research organisation (CRO) specialising in high-quality preclinical drug discovery services, particularly in ion channel biology, cardiac safety profiling, and neuroscience services.
Recent News
Secured £2.7m in new equity financing in 2024 to expand laboratories and services, and appointed Lee Patterson as the new CEO in December 2024.
MRN Limited
About
Information technology consultancy activities
Recent News
MyHealthChecked PLC
About
A United Kingdom-based consumer home-testing healthcare company offering at-home rapid tests, DNA, RNA, and blood sample collection kits.
Recent News
Celebrated test kit registration in January 2025
Niox Group PLC
About
A medical device company focused on point of care asthma diagnosis and management[4]
Recent News
Announced results for the year ended 31 December 2023, highlighting revenue growth and other financial highlights[4]
Novacyt S.A.
About
Novacyt SA is an international molecular diagnostics company that develops, manufactures, and commercialises a range of molecular assays and instrumentation. It provides integrated technologies and services focused on genomic medicine, including human health, animal health, and environmental sectors.
Recent News
Completion of acquisition of Yourgene Health plc, further expansion of cost reduction programme, and London Vet Show: Launch of animal multiplex assays
Oncimmune Holdings PLC
About
Oncimmune Holdings PLC is a cancer detection company engaged in developing and commercializing its proprietary EarlyCDT platform technology, primarily focused on the growing fields of immuno-oncology, autoimmune disease, and infectious diseases.
Recent News
Shares in Oncimmune Holdings PLC climbed 11% on Friday after it announced certain updates.
Optibiotix Health PLC
About
OptiBiotix Health Plc is a life sciences company operating in the modulation of the human microbiome, developing technologies and products for food ingredients, supplements, and active compounds to impact human physiology and health.
Recent News
OptiBiotix Health PLC Launch of Dr Morepen LightLife in India, Directorate Change, Issue of Options[3]
Oxford BioDynamics PLC
About
An international biotechnology company advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases.
Recent News
Announced a leadership change with the resignation of CEO Dr. Jon Burrows and the appointment of Iain Ross as Executive Chairman, and is seeking additional funding through a potential equity raise.
Oxford Metrics PLC
About
Oxford Metrics plc operates as a smart sensing and software company in the United Kingdom and internationally. It engages in the development, production, and sale of computer software and equipment for the engineering, entertainment, and life science markets.
Recent News
Oxford Metrics PLC agreed to buy Sempre Group Holdings Ltd for up to GBP5.5 million to add to its smart manufacturing division.
Perspectum
About
Perspectum is a global medical technology company delivering advanced digital technologies to help clinicians provide better care for patients with chronic metabolic diseases, multi-organ pathology, and cancer. It focuses on precision medicine using advanced imaging and genetics to enable early detection, diagnosis, and targeted treatment.
Recent News
Completed a $36 million first close of its Series C funding round led by Oppenheimer Holdings in January 2023.
Physiomics PLC
About
A leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions
Recent News
Completed a placing to fund growth opportunities, launched a WRAP Retail Offer, and awarded a new contract with a globally recognised pharmaceutical client
Poolbeg Pharma PLC
About
Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company focused on acquiring, developing and commercialising innovative medicines for unmet medical needs, particularly in areas such as cancer immunotherapy-induced cytokine release syndrome, infectious diseases, and metabolic conditions.
Recent News
Entered into non-binding discussions for an all-share acquisition by HOOKIPA Pharma Inc. and proposed collaboration with Gilead Sciences for investment up to $8.7495 million.
Prime Global Medical Communications
About
A global medical communications and market access group providing full-service professional communications, including healthcare strategy and consultancy, scientific and medical communications, consumer health, patient-integrated science, and market access.
Recent News
Acquired Aventine Consulting to bolster its U.S. evidence and access presence
Proteome Sciences PLC
About
Proteome Sciences is an established leader in CRO outsourced services to quantitate proteins and peptides in complex solid and fluid biological samples. We use high sensitivity proprietary technologies to detect biomarkers across major human diseases in areas of significant unmet need where biomarkers have the potential to transform disease management and treatment.
Recent News
Proteome Sciences has secured a contract win from a US biopharmaceutical company using the Company’s mass spectrometry services for the analysis of samples for an on-going clinical trial. The company has also completed the installation and setup of equipment in its new US laboratory in San Diego, California, and is now fully operational.
Proton Motor Power Systems PLC
About
The company is focused on stationary solutions, as well as mobile, maritime, and rail applications. It engages in the development and manufacturing of fuel cells, stacks, and hybrid systems to implement customized solutions.
Recent News
Proton Motor Power Systems PLC intends to delist from AIM and wind down its operations by the end of 2024 due to failure to secure additional funding.
Provexis PLC
About
Specialising in functional food and dietary supplements, particularly the patented natural extract from tomatoes known as Fruitflow®
Recent News
Revenue more than doubled in the six months to September 30, 2024, and the company is looking forward to expansion, including a potential entry into the Chinese market and the launch of an Irish subsidiary
Qualasept Holdings
About
Qualasept Holdings Limited operates in the activities of other holding companies sector. It is the parent company of several subsidiaries including Bath ASU, Pharmaxo, and Microgenetics.
Recent News
Provided Series A financing to Event Store in 2020 for the development of EventStoreDB and Event Store Cloud
Quay Pharmaceuticals
About
A contract development manufacturing organisation (CDMO) specializing in formulation research and development, clinical and commercial manufacturing of new chemical entities, biologicals, and live biotherapeutics.
Recent News
Acquired by SGS to become the global Centre of Excellence for Formulation, Research and Development within SGS Health Science.
Quotient Sciences
About
Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway, including pre-formulation screening, formulation development and optimization, first-in-human trials, and clinical and commercial manufacturing services.
Recent News
Announced major changes to its commercial and scientific executive leadership team, including new appointments of Dr. Andrew Lewis as Chief Scientific Officer, Kieron Hall as Chief Marketing Officer, and Eric Bironneau as Chief Business Officer in March 2024.
Renalytix PLC
About
An artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs[5]
Recent News
Potential takeover fell through; advanced discussions with key stakeholders; delisting risk from Nasdaq; transition to OTCQB Venture Market[2][3]
Richmond Pharmacology
About
A UK-based contract research organization conducting early phase clinical trials and clinical research, known for its speed and precision in bringing life-changing therapies to market.
Recent News
Richmond Pharmacology has dosed the first person in the world with a new genetic therapy for ATTR Amyloidosis using CRISPR-Cas9 technology and has undergone a brand refresh, changing its name to simply 'Richmond'.
Sareum Holdings PLC
About
Sareum Holdings plc is a biotechnology company focused on developing next-generation kinase inhibitors for autoimmune diseases and cancer, particularly targeting TYK2 and JAK1 pathways.
Recent News
Termination of the licensing agreement for its cancer drug candidate SRA737 by a U.S.-based biopharma company, effective in March 2025. The company is now focusing on its in-house projects, especially SDC-1801.
Shield Therapeutics PLC
About
A patient-focused, commercial stage pharmaceutical company on a mission to improve the lives of people suffering from iron deficiency, enabling them to enjoy the things that make a difference in their everyday lives. The lead medicine is ACCRUFeR® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anemia.
Recent News
KYE Pharmaceuticals Inc. filed a New Drug Submission for Accrufer® in Canada, and the Korean Food and Drug Administration agreed that a single pharmacokinetic study is the only additional study needed for Accrufer®
SkinBioTherapeutics PLC
About
A life science company focused on skin health, harnessing the microbiome for human health through its proprietary platform technology, SkinBiotix®.
Recent News
Acquired Bio-Tech Solutions Limited for £1.25 million on October 11, 2024
Surgical Innovations Group PLC
About
Manufacturer and distributor of medical technology, focusing on Minimally Invasive Surgery (MIS) and providing sustainable solutions to reduce the environmental footprint of surgery
Recent News
Announced record revenue of GBP12.0 million, signed two exclusive multi-year UK distributing agreements, and reported a pretax loss of GBP728,000 in 2023
Sygnature Discovery
About
A world-leading integrated drug discovery and non-clinical solutions provider, offering expertise across a broad range of therapeutic areas and biological target classes.
Recent News
Acquired NuChem Sciences, a leading discovery CRO in North America, to expand its global footprint
Synairgen PLC
About
Synairgen is a specialist respiratory biotech company developing an investigative inhaled interferon beta candidate (SNG001) for severe viral lung infections.
Recent News
Proposed fundraising to raise a minimum of £18 million and a maximum of £19 million through the conditional subscription of new Ordinary Shares.
Tissue Regenix Group PLC
About
A pioneering, international medical technology company focusing on the development of regenerative products utilising dCELL® and BioRinseTM technologies.
Recent News
Extended distribution agreement with Arthrex, Inc. (November 2024)
Trellus Health PLC
About
Trellus Health plc is a United Kingdom-based health services company, which is engaged in providing solutions and services for chronic condition management, particularly focusing on chronic costly GI conditions such as inflammatory bowel disease (IBD)[2]
Recent News
Trellus Health PLC shares surged on Tuesday after the company announced a collaboration with Johnson & Johnson Health Care Systems Inc to integrate its Trellus Elevate platform into a patient support programme in the US[3][5]
Tristel PLC
About
Tristel is an infection prevention company that develops innovative solutions to prevent the transmission of microbes using chlorine dioxide as a high-performance disinfectant.[1]
Recent News
Tristel reported FY24 revenue of GBP41.9M and EPS of GBX13.54[4]
ValiRx PLC
About
A biopharmaceutical company that develops oncology therapeutics and companion diagnostics, including products like VAL201 for prostate cancer and VAL401 for lung cancer.
Recent News
Acquisition of patents and intellectual property from FIT Biotech and a joint-venture agreement with Alpha Blue Ocean
Venture Life Group PLC
About
Develops and commercializes healthcare products in the self-care market globally
Recent News
Acquired Health and Her Ltd. from Wales Angel Co-investment Fund and Development Bank of Wales Plc on October 30, 2024
Vianet Group PLC
About
Vianet Group provides data insight and reporting, with over 300 customers and more than 230,000 devices connected to their platform.
Recent News
Announced the repurchase and cancellation of 10,000 ordinary shares; acquired the trade and assets of Beverage Metrics
Waymade
About
A global specialty pharmaceutical business focusing on product development, licensing and commercialisation of generic and niche medicines.
Recent News
Waymade Capital forms part of a consortium led by Duke Street to acquire Medi-Globe Corp, a German medical devices business.
Xeros Technology Group PLC
About
Xeros Technology Group PLC is a United Kingdom-based company engaged in providing technology solutions for the laundry and apparel industries, focusing on developing patented technologies to reduce the environmental impact of how industries make and care for clothes.[2]
Recent News
Change in major shareholdings, including adjustments by First Equity Limited and Premier Miton Group[3][4]
Zecare
About
Recent News
Ellipses Pharma
About
A global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug development model that combines unbiased vetting of potential drug candidates with an uninterrupted flow of capital to minimize the time it takes to advance drugs through the clinical trial process and reach patients.
Recent News
Ellipses Pharma launched a pioneering clinical trial programme in the Middle East, focusing on its next-generation selective RET inhibitor (EP0031/A400) for RET-altered tumours, and entered into an exclusive licensing agreement with SunRock Biopharma for a first-in-class bifunctional HER3:TRAIL fusion protein (EP0017)[2][3]
CellCentric
About
CellCentric is a clinical stage biotech company focused on the development of a p300/CBP inhibitor to treat specific cancer types, notably multiple myeloma.
Recent News
Presented latest clinical data on inobrodib, a novel oral drug, at ASH24, showing promising efficacy and safety in treating multiple myeloma.
Evox Therapeutics
About
A biotechnology company focused on harnessing and engineering the natural delivery capabilities of extracellular vesicles (exosomes) to develop a new class of biotherapeutics for treating severe diseases, particularly targeting the brain and central nervous system.
Recent News
Dr. Per Lundin appointed as Chief Executive Officer, acquisition of engEx-AAV™ technology platform from Codiak Biosciences
Ascend Gene & Cell Therapies
About
Ascend is a specialist AAV development partner supporting the next-generation of life-science innovators in bringing gene therapy products to patients. They offer process development, clinical manufacturing, and analytical and regulatory support for biotech companies.
Recent News
Expanded US footprint through merger with Advanced BioScience Laboratories, and raised over $130M in funding to enhance manufacturing capabilities.
AviadoBio
About
AviadoBio is a pioneering startup in the healthcare sector, specifically in the field of gene therapy, focused on developing and delivering innovative gene therapies for individuals suffering from severe neurodegenerative diseases such as frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).
Recent News
Astellas and AviadoBio announced an exclusive option and license agreement for AVB-101, an investigational, AAV-based gene therapy in Phase 1/2 development for frontotemporal dementia with mutations in the progranulin (GRN) gene.
OMass
About
A biotechnology company harnessing native mass spectrometry to drive drug discovery, focusing on rare and immunological diseases, and developing small molecule therapeutics using its proprietary OdyssION™ technology platform.
Recent News
Selected by Fierce Biotech as a ‘Fierce 15’ winner for 2024, advancing its lead program for Congenital Adrenal Hyperplasia and expanding its pipeline in immunology
Bit.bio
About
Bit Bio is a synthetic biology company providing human cells for research, drug discovery and cell therapy. The company applies a patented safe harbour gene-targeting approach to inducibly express transcription factor combinations that reprogram human induced pluripotent stem cells (iPSCs) into highly defined and mature human cell types.
Recent News
bit.bio's opti-ox™ technology has gained unprecedented global patent coverage, including approvals in the U.S., China, and South Korea, and pending in other key markets like Australia and Japan.
Osler Diagnostics
About
Osler Diagnostics is a healthcare technology startup aiming to transform global healthcare through its innovative product, the Osler Origin®, a portable diagnostic device capable of performing a wide range of tests in a rapid, low-cost, and easy-to-use manner.
Recent News
M&G’s Catalyst strategy has invested in Osler Diagnostics to support the advancement of the Osler Origin product through regulatory activities and towards market launch.
Touchlight
About
Touchlight is a biotechnology company focused on the production of synthetic DNA vectors, specifically its proprietary doggybone DNA (dbDNA™), which is used in genetic medicine, including viral vectors, mRNA, and DNA-based therapies.
Recent News
Touchlight completed the expansion of one of the world’s largest DNA manufacturing facilities in London, UK, and received FDA clearance for an Investigational New Drug (IND) application using dbDNA.
Crescendo Biologics
About
Crescendo Biologics is a clinical-stage immuno-oncology company focused on developing novel T cell-enhancing therapeutics, particularly using its proprietary Humabody® VH platform.
Recent News
Secured $32 million to expand the Phase 1b clinical trial of CB307 with a new pembrolizumab combination expansion cohort in PSMA+ solid tumours.
Pulmocide
About
Pulmocide is a biopharmaceutical company focusing on the discovery and development of inhaled medicine for the treatment of life-threatening fungal and viral infections of the respiratory tract.
Recent News
Pulmocide announced a presentation at the 43rd Annual J.P. Morgan Healthcare Conference and is conducting Phase 3 clinical trials for opelconazole for the treatment of Invasive Pulmonary Aspergillosis[3]
Quell Therapeutics
About
Quell Therapeutics is a biotechnology company focused on developing engineered T regulatory (Treg) cell therapies for autoimmune diseases and preventing rejection in organ transplantation.
Recent News
Collaboration with AstraZeneca to develop T-regulatory cell therapies for Type 1 diabetes and inflammatory bowel disease.
F2G
About
F2G is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening rare fungal infections.
Recent News
F2G secured $100 million in funding led by AMR Action Fund to advance late-stage development and commercialization of its novel antifungal drug candidate, olorofim.
TauRx Pharmaceuticals
About
TauRx Pharmaceuticals Ltd is a life sciences/pharmaceutical company focused on developing treatments for neurodegenerative diseases, particularly Alzheimer's disease, through protein aggregation inhibitors.
Recent News
Dundee Corporation sold 8,000 shares of TauRx Pharmaceuticals Ltd to a private investor for US$1 million in September 2024.
Artios Pharma
About
Artios is a leading independent DNA Damage Response company committed to discovering and developing groundbreaking DDR therapeutics to help patients suffering from a broad range of devastating and difficult-to-treat cancers.
Recent News
Artios Announces Initiation of Phase 2 Randomized Trial for ATR Inhibitor ART0380 plus Gemcitabine in Patients with Platinum Resistant Ovarian Cancer
Closing Remarks
The UK pharmaceutical and biotech industry is a dynamic and innovative sector with a strong global presence. These companies are not only major contributors to the UK economy but also play a vital role in addressing global healthcare challenges. The industry faces challenges such as rising production costs, increased competition, and patent expirations. However, it also benefits from a strong research and development focus, government support, and a growing demand for medicines. The UK's biotech sector is particularly noteworthy, with the country leading Europe in the number of new biotech start-ups.
Looking ahead, the UK pharmaceutical and biotech industry is poised for continued growth and innovation. The sector is likely to see further advancements in areas such as cell and gene therapy, personalized medicine, and the use of artificial intelligence in drug discovery and development. These advancements will not only benefit patients in the UK but also contribute to the global healthcare landscape. The UK's strong research base, its vibrant biotech clusters, and its commitment to innovation position it as a global leader in the pharmaceutical and biotech industry. One interesting observation from the research is the variation in pharmaceutical spending as a proportion of overall health expenditure among different nations. The UK's spending in this area is relatively low compared to some other European countries. This could indicate effective cost-containment measures or a lower emphasis on pharmaceutical interventions in the UK healthcare system. Further research could explore the reasons for this variation and its implications for patient access to medicines and healthcare outcomes.